Diabetes Glimepiride Powder Pharmaceutical Glimepiride Intermediate Glimepiride

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Glimepiride
• Product Name: Glimepiride
• Name: Glimepiride Powder
• Appearance: White Fine Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 93479-97-1
• Mf: C24h34n4o5s
• MW: 490.61556
• Density: 1.29
• Melting Point: 212-214 C
• Boiling Point: 677.0+-65.0 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: Negotiable
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

Diabetes Glimepiride powder Pharmaceutical Glimepiride Intermediate Glimepiride

Product Description

Product Details

 

Product Name	Glimepiride
CAS No.	93479-97-1
MF	C24H34N4O5S
MW	490.61556
Appearance and shape	White fine Powder

Glimepiride is a third-generation sulfonylureas long-acting anti-diabetes drug.  The main mechanism of its hypoglycemic effect is to stimulate the secretion of by beta cells of the pancreas and partially increase the sensitivity of surrounding tissues.  This product binds to receptor and dissociates faster than glyburide, and causes less severe hypoglycemia.  Its mechanism is through and sulfonyl urea receptors on the surface of the pancreatic beta cells (relative molecular mass of 6.5 x 104 protein), the receptor and ATP sensitive K + (KATP) channel phase coupling, pushing the KATP channel close, cause cell membrane depolarization, makes the open voltage dependent calcium channel, Ga2 + internal flow and lead to the release, and inhibit the synthesis of liver glucose.  Recent studies have shown that different sulfonylurea coal drugs have different affinities with KATP.  The following order: Glenn beauty urea > tolbutamide > sulfonyl chloride propyl urea.  In addition, it could be a glucose transporter factor 1, 4 caused by two kinds of protein expression is increased.  Due to Glenn beauty of urea to cardiovascular KATP channels in the weaker than Glenn wave urea, gliclazide pass column pyrazine.  So cardiovascular adverse reactions are also rare.

Application & Function

 

Glimepiride is a medium- to long-acting sulfonylureaantidiabetic drug. Glimepiride (Glimer) is indicated to treat type 2 diabetes mellitus;   its mode of action is to increase in'sulin production by the pancreas.   It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able to produce in'sulin.  Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas, and during pregnancy.

Specification